**Correction to: BMC Cancer**

**https://doi.org/10.1186/s12885-019-5687-0**

Following publication of the original article \[[@CR1]\], the authors reported the following errors in the article.In Table [2](#Tab1){ref-type="table"}, the layout has been updated. The corrected Table [2](#Tab1){ref-type="table"} is supplied below:The legend for Fig. [3](#Fig1){ref-type="fig"} has been adapted for clearer readability. The updated legend is as follows:The competing interests statement has been updated below.Table 2Progression-free survival by HER2 expression subgroupsTrastuzumab + taxane (Control)T-DM1\
(T-DM1)T-DM1 + pertuzumab\
(T-DM1+P)No. patients / No. patients with PFS eventMedian PFS (mo)No. patients / No. patients with PFS eventMedian PFS (mo)HR vs. trastuzumab + taxane (97.5% CI)^a^No. patients / No. patients with PFS eventMedian PFS (mo)HR vs. trastuzumab + taxane (97.5% CI)^a^HR vs. T-DM1 + placebo (97.5% CI)^a^All patients^b^ IHC 3+333/20914.4340/21514.60.93 (0.75--1.16)331/19516.70.83 (0.67--1.04)0.90 (0.72--1.12) IHC 2+27/1912.625/207.31.13 (0.55--2.32)29/208.31.25 (0.61--2.59)0.98 (0.48--2.02)IHC 2+/3+ patients combined^c^ Focal IHC 2+/3+ (10--29%)^d^14/812.412/106.41.51 (0.52--4.40)15/127.51.41 (0.50--3.94)1.00 (0.38--2.65) Heterogeneous IHC 2+/3+ (30--79%)35/2710.637/258.31.04 (0.55--1.94)33/206.31.11 (0.57--2.17)0.91 (0.46--1.78) Homogeneous IHC 2+/3+ (≥80%)311/19314.6316/20014.70.92 (0.74--1.16)312/18317.80.82 (0.65--1.04)0.89 (0.71--1.13)IHC 3+ patients only Focal IHC 3+ (10--29%)^d^9/58.311/78.31.20 (0.32--4.50)8/74.25.11 (0.99--26.40)2.28 (0.60--8.71) Heterogeneous IHC 3+ (30--79%)44/2910.545/3410.01.15 (0.65--2.03)29/1617.80.79 (0.39--1.60)0.65 (0.33--1.29) Homogeneous IHC 3+ (≥80%)280/17514.6284/17415.20.89 (0.70--1.14)294/17217.70.82 (0.65--1.05)0.92 (0.73--1.17)^a^Unstratified hazard ratio^b^Five patients with IHC 0/1+ and five patients with unknown IHC status are not included in this table^c^Categories were based on IHC subgroup and then combined^d^Compared with the overall population, samples with focal HER2 expression were more likely to express mutated PIK3CA and lower levels of HER2 mRNA *CI* confidence interval, *HER2* human epidermal growth factor receptor 2, *HR* hazard ratio, *IHC* immunohistochemistry, *NE* not estimable, *P* pertuzumab, *PFS* progression-free survival, *PIK3CA* phosphoinositide 3-kinase catalytic subunit alpha, *T-DM1* trastuzumab emtansineFig. 3Kaplan--Meier curve of PFS in subgroups defined by the presence/absence of negatively impacting biomarkers.\*\*Biomarkers were considered negatively prognostic of response to HER2-targeted treatment based on their association with a numerical decrease in PFS. Specifically, these included expression of mutated PIK3CA, low HER2 mRNA level (≤median), and focal HER2 distribution. Patients without negative markers were those with nonmutated PIK3CA, high HER2 mRNA levels (\>median), and non-focal (i.e., heterogeneous or homogenous) distribution of HER2. Patients with negative markers were those with mutated PIK3CA, low HER2 mRNA levels (≤median), and focal HER2 distribution. *HER2* human epidermal growth factor receptor 2, *PIK3CA* phosphoinositide 3-kinase catalytic subunit alpha, *PFS* progression-free survival, *T-DM1* trastuzumab emtansine
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